Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Growth-modulatory Effects of Heparin and VEGF165 on the Choriocarcinoma Cell-line JEG-3 and its Expression of Heparanase

MICHAEL K. BOHLMANN, JANA-CHRISTIN HOERSTER, DIANA BUNDSCHUH, PHILIPP BOEMICKE, DOERTE W. LUEDDERS and FRANK KÖSTER
Anticancer Research December 2014, 34 (12) 7071-7076;
MICHAEL K. BOHLMANN
1Department of Obstetrics and Gynaecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.bohlmann@uksh.de
JANA-CHRISTIN HOERSTER
1Department of Obstetrics and Gynaecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIANA BUNDSCHUH
1Department of Obstetrics and Gynaecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PHILIPP BOEMICKE
1Department of Obstetrics and Gynaecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOERTE W. LUEDDERS
2Department of Obstetrics and Gynaecology, University Hospital Oldenburg, Oldenburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANK KÖSTER
1Department of Obstetrics and Gynaecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Expression of heparanase (HPSE) in tumor cells is strongly associated with invasion, metastasis and angiogenesis. It also plays a key role during pregnancy, in processes of implantation as well as placentation. Vascular endothelial growth factor (VEGF) and heparin are known to alter HPSE expression, with heparin given prophylactically to women with a history of placenta-mediated complications in subsequent pregnancies. Materials and Methods: We examined the growth-modulatory effects of different concentrations of heparin and VEGF on the choriocarcinoma cell-line JEG-3 and the expression of heparanase under VEGF and heparin by proliferation assays, PCR, and western blot. Results: Proliferation of JEG-3 cells was induced by heparin in a dose-dependent manner, whereas highly concentrated VEGF led to a decreased cell proliferation. Both agents did not influence the HPSE-expression. Conclusion: The presumed pregnancy-protecting effects of heparin may partially be due to an increase of trophoblast proliferation and not via regulation of HPSE expression.

  • Heparin
  • VEGF
  • choriocarcinoma
  • heparanase
  • proliferation
  • PCR

Heparanase (HPSE) is an endo-β-d-glucuronidase, involved in degradation and remodelling of the extracellular matrix (1). Cleaving heparan sulfate side chains is among its mainly examined functions (2). HPSE has been found in placental tissue of both humans (3-5) and animals (6). HPSE is considered to play a key role in processes of implantation. as well as placentation (7). Its expression is not restricted to the placenta as HPSE is expressed in platelets, keratinocytes and activated cells of the immune system under physiological conditions, whereas most normal epithelia stain negative for HPSE (1, 8). HSPE has been described to be over-expressed in both inflammatory (9) and autoimmune diseases and in a variety of cancers (10) with increased rates of tumour angiogenesis (10), invasiveness (11) and metastatic behaviour (12) associated with a HPSE over-expression, which is in fact the case for human choriocarcinoma (13). Recently, there have been reports about an altered expression of the HPSE gene after heparin incubation in combination with high glucose in human aortic endothelial cells (14). Heparins themselves are known to exert a wide range of effects beyond anti-coagulation at the placental and decidual level, which has especially been investigated in association with questions of implantation failure and recurrent miscarriages (15).

In women suffering from the anti-phospholipid syndrome (APS), the application of heparin has been shown to increase the live-birth rate in combination with low-dose acetyl salicylic acid. Such a beneficial effect had also been postulated for the isolated application of heparin in patients with other subtypes of early (16-17) and late pregnancy complications (18), such as non-recurrent and recurrent miscarriages, as well as placenta-associated diseases, e.g. preeclampsia. It is established that preeclampsia goes along with a reduced invasion of the trophoblast into the maternal decidua (19), implying that a pro-invasive protein, such as HPSE, might play a role in altering this process (20). Additionally, recent reports have described that vascular endothelial growth factor (VEGF), regarded necessary for tumor vascularity and metastasis, shows mutual enhancing effects with HPSE (21). VEGF has been described to alter the expression of pro-invasive matrix metalloproteinases in the choriocarcinoma cell-line JEG-3 (22) and its subtype A (VEGFA) is thought to be secreted by (23) and to stimulate the proliferation of both the trophoblast (24) and choriocarcinoma cells (25).

As HPSE itself is expressed in the implantation window of non-conceptual cycle endometrium (26), we sought to find out whether heparin and VEGFA may exert pregnancy-protective effects by altering the expression of HPSE.

Taking into account the similarities between the proliferative, migratory and invasive properties of placental and cancer cells (27), immortalized human choriocarcinoma cells served as a surrogate for the primary trophoblast in accordance to other publications (28-32).

Materials and Methods

Cell culture. The human choriocarcinoma cell line JEG-3 (DSMZ, Braunschweig, Germany) was cultured at 37°C, in a humidified atmosphere with 5 % CO2. JEG-3 were grown in Ham's F12 (PAA Laboratories GmbH, Cölbe, Germany) supplemented with 10 % fetal calf serum (FCS; PAA Laboratories GmbH) and 1 % (v/v) penicillin/streptomycin (10,000 Units/ml/10 mg/ml; PAA Laboratories GmbH).

Growth experiments. 3,000 cells per well were plated in growth medium on 96-well-plates (Sarstedt AG & Co., Nümbrecht, Germany). Twenty-four h later, the medium was replaced by FCS-free medium. After 1 h various concentrations of heparin (0.01, 0.1, 1, 10, 100 and 1.000 U/ml; Sigma-Aldrich, Steinheim, Germany) or the VEGFA splice variant VEGF165 (1, 10 and 100 ng/ml; Reliatech, Wolfenbüttel, Germany), responsible for its biological activity, were added by a further exchange of the media, containing FCS concentrations of 1% and 3.3%. The growth experiments were performed in a general atmospheric incubator with 5% CO2 and under hypoxic conditions with 2% O2 and 5 % CO2 in a hypoxia chamber THC08 124 (Toepffer Lab Systems, Göppingen, Germany). Each experiment was repeated twice with sextuplicates of culture wells. After incubation times of 24, 48 and 72 h the cells were measured in MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich) assays as described elsewhere (33).

Expression of heparanase (HPSE) mRNA in JEG-3 under the influence of heparin and VEGF165 in normoxia and hypoxia. The mRNA expression of HPSE and its regulation by heparin, VEGF165 and hypoxia was evaluated by means of the quantitative reverse transcription polymerase chain reaction (qRT-PCR). JEG-3 were plated on 6-well plated by 600,000 cells per well in growth media. Twenty-four h later, media were replaced by media containing heparin (0.1 U/ml), VEGF165 (100 ng/ml) or control medium with 1% or 3.3% FCS for 3 h. Experiments were performed in duplicates. The respective concentrations of heparin and VEGF165 were chosen due to their pronounced effects in the proliferation experiments. Total RNA was isolated by using QIAzol (Qiagen, Hilden, Germany). One μg RNA was reverse-transcribed with Superscript-II (Invitrogen, Karlsruhe, Germany) using random-primers. qPCR was performed by using Platinum SYBR Green qPCR Super Mix-UDG (Invitrogen) on the qPCR system Opticon 2 (BioRad, Munich, Germany). To quantify the HPSE gene the following primer pair was used according to GenBank Accession No. NM_006665: 5’-TCC TGC GTA CCT GAG GTT TG-3’ (forward); 5’-CAA CCG TAA CTT CTC CTC CAC-3’ (reverse). Succinate dehydrogenase complex subunit A (SDHA; forward: 5’-TGG GAA CAA GAG GGC ATC TG-3’ and reverse: 5’-CCA CCA CTG CAT CAA ATT CAT G-3’) and hypoxanthine-guanine phosphoribosyltranferase (HPRT; forward: 5’-TCA GGC AGT ATA ATC CAA AGA TGG T-3’ and reverse: 5’-AGT CTG GCT TAT ATC CAA CAC TTC G-3’) were used for normalization. All primers were synthesized at Metabion (Martinsried, Germany). The PCR protocol consisted of 40 cycles of 15 s at 95°C and 30 s at 60°C. Each sample was tested in duplicate. The reaction efficiency of every primer pair had been determined using dilution series with a representative pool of cDNAs (Table I) as proposed by Pfaffl (34). Data were further processed with the excel-based program REST-MCS©-version 2 (www.gene-quantification.info).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Results of the q-RT-PCR of HPSE in JEG-3 cells, treated with 0.1 U/ml heparin (upper panel) or with 100 ng /ml VEGF165 (lower panel).

Immunochemical analysis of heparanase. Total protein (HPSE) was extracted by using the Mammalian Protein Extraction Buffer (GE-Healthcare, München, Germany). Twenty μg of the extractions were electrophoresed and blotted onto a nitrocellulose membrane. The membrane was blocked in TBST-buffer and 5% (w/v) nonfat dry milk and incubated at 4°C overnight with a 1:4000 diluted monoclonal anti-human heparanase 1 (HPA1) antibody (Clone HP3/17; Acris, Herford, Germany). Following 3 times washing for 5 min in TBST-buffer, a secondary antibody incubation was performed for 1 h at room temperature with the horseradish peroxidase-linked sheep anti-mouse antibody diluted 1: 4000 (NA-931; GE-Healthcare, Munich, Germany). After 3 more washings, the immunoreaction was developed using the immobilon-Western-HRP substrate (Millipore, Schwalbach, Germany) and visualized on hyperfilm-ECL (GE-Healthcare).

Statistics. Statistical analyses of growth experiments were performed with GraphPad-Prism 5 (GraphPad, La Jolla, CA, USA) using the monofactorial ANOVA-variance analysis and Dunnett's post-hoc test. A p-value <0.05 was considered as statistically significant. Outliers were identified with the GraphPad Outlier calculator, applying the Grubb's test, and excluded from further analysis.

Results

Influence of heparin on the proliferation of JEG-3 cells. The proliferation of JEG-3 cells was significantly increased by heparin at concentrations of 0.01 to 10 U/ml at atmospheric conditions and a FCS concentration of the medium of 3.3% (Figure 1A). However, heparin concentrations of 100 and 1,000 U/ml showed a return to basic levels of proliferation. Accordingly, heparin also increased cell proliferation at concentrations of 0.01 to 0.1 U/ml at hypoxic conditions and a FCS concentration of the medium of 1% (Figure 1B).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A) Induction of proliferation of JEG-3 cells by heparin at normoxia and a FCS concentration of 3.3%. B) Under hypoxic conditions and the reduction of FCS to 1%, heparin concentrations of 0.01 and 0.1 U/ml caused a significant induction of cell proliferation. Co, control; *p<0.05; p<0.01; ***p<0.001.

Influence of VEGF165 on the proliferation of JEG-3 cells. The proliferation of JEG-3 cells was significantly decreased by VEGF165 at concentrations of 10 and 100 ng/ml at atmospheric conditions and a FCS concentration of the medium of 3.3% (Figure 2A) and at 100 ng/ml in hypoxia (Figure 2B).

HPSE expression. As shown by western blot analysis, HPSE is expressed in JEG-3 cells (Figure 3). No significant differences in the HPSE mRNA-expression were detected after incubation with heparin or VEGF165 at the respective concentrations (Table I).

Discussion

Heparin, a negatively-charged glycosaminoglycan, has been described to exert anti-metastatic effects on tumor cells (35). However, we were able to show a significant increase of proliferation of choriocarcinoma cells after incubation with heparin at distinct concentrations, a result that was – to the best of our knowledge – not described before. The stimulation of proliferation, depending on the concentration of heparin, is comparable to results from other cell-lines, e.g. human osteoblasts (36). In our setting, heparin at most concentrations failed to compensate the anti-proliferative effects of hypoxia but was still able to lead to a significantly increased cell proliferation at 0.01 U/ml.

When reducing both the concentrations of oxygen and FCS to induce a lack of nutrients, heparin at low concentrations again was able to compensate partially the lack of nutrients and promote cell growth. This observation could not be confirmed for higher concentrations of heparin, which may be explained by the fact that heparin can also exert direct cytotoxic effects on tumors cells (35).

It has been shown that heparin may induce trophoblastic invasiveness in vitro by altering the expression of matrix metalloproteinases and tissue inhibitors (37), thus possibly promoting a protective effect for the developing pregnancy. However, clinical applications of heparin (s) in pregnancies threatened by miscarriage or complications, such as preeclampsia, have failed to show consistent results (16-18, 38-47). It is especially surprising that heparin may exert a protective effect against placenta-mediated complications when applied in the second trimester of pregnancy (18); when the invasion of the trophoblast is already completed. Nevertheless, our results showing an increase of trophoblastic proliferation may prompt further investigations in the field of heparin application in early pregnancy to prevent late (r) complications in patients at risk.

Heparins have been described as strong inhibitors of heparanase (HPSE) (48) showing to interfere in its transcriptional regulation (14) with chemically modified heparins, such as SST0001, preclinically used to inhibit tumor cell growth and angiogenesis (49). This regulation of HPSE expression by heparin could not be observed in our setting.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

A) Reduction of proliferation of JEG-3 cells by VEGF165 at normoxia and a FCS concentration of 3.3%. B) Under hypoxic conditions, a VEGF165 concentration of 100 ng/ml caused a significant reduction of cell proliferation. Co, control; *p<0.05; **p<0.01; ***p<0.001.

HPSE has been shown to increase VEGF expression in non-malignant and malignant cells (50, 51). However, an enhancing effect of VEGF on the expression of HPSE, as seen in melanoma cell lines (21), could not be demonstrated in our setting.

Hypoxia has been described to induce expression of VEGFA in human choriocarcinoma cells, with VEGF thought to increase the invasive capacity in these cells (52). Interestingly, the splice variant of VEGFA, VEGF165, does not lead to a proliferation of JEG-3 cells in our setting; it reduced their growth at higher concentrations. This result seems to stand in contrast to experiments with the BeWo choriocarcinoma cell line where VEGF leads to an increased cell proliferation (25). However, as shown in BeWo cells, endogenous nitric oxide (NO) production induced by exogenous VEGF at a concentration of 10 ng/ml down-regulates the otherwise VEGF-stimulated proliferation. Therefore, our approach with the aforementioned and even higher concentration of VEGF might explain their growth-inhibiting effects on JEG-3 cells.

Since the first characterization of HPSE in the placenta (53) deriving from trophobalstic tissue, some studies have investigated its expression in human placental tissue (2, 4, 54, 55). Placental HPSE has been proven to be expressed in all trimesters of both physiological and pathological pregnancies; however, no findings on its concentrations under the various circumstances were reported (4). Nadir and colleagues (2) proved that placental tissue form early miscarriages overexpresses HPSE. Furthermore, trophoblast cells incubated with exogenous recombinant HPSE show a significantly altered expression pattern of haemostatic factors, such as tissue factor pathway inhibitor 1 and 2. These factors are thought to be involved in early pregnancy complications, such as (recurrent) miscarriages (2). However, as the alterations were detected in early pregnancy tissue and cell culture, the results cannot be automatically attributed to complications in the second or third trimester of pregnancy, such as preeclampsia.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Protein expression of heparanase (HPSE) in JEG-3 cells as shown in western blot. OVCAR-3 cells are shown as a positive control.

Since in our setting such a regulation could not be shown, heparin must exert its growth-stimulatory effects through other pathways. On the other hand, as there are striking similarities between the invasion of the trophoblast and that of cancer cells, with the latter stimulated by an increased heparanase expression (10), the otherwise observed reduction of HPSE expression by heparins is lacking in the trophoblast.

Acknowledgements

The Authors would like to thank Stephan Polack who contributed substantially to the accurate performance of the experiments and Professor Jan Rupp for supplying the hypoxia chamber.

Footnotes

  • Conflicts of Interest

    None.

  • Received August 1, 2014.
  • Revision received September 22, 2014.
  • Accepted September 26, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Vlodavsky I,
    2. Friedmann Y
    : Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341-347, 2001.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Nadir Y,
    2. Henig I,
    3. Naroditzky I,
    4. Paz B,
    5. Vlodavsky I,
    6. Brenner B
    : Involvement of Heparanase in early pregnancy losses. Thromb Res 125: e251-257, 2010.
    OpenUrlPubMed
  3. ↵
    1. Klein U,
    2. von Figura K
    : Partial purification and characterization of heparan sulfate specific endoglucuronidase. Biochem Biophys Res Commun 73: 569-576, 1976.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Haimov-Kochman R,
    2. Friedmann Y,
    3. Prus D,
    4. Goldman-Wohl DS,
    5. Greenfield C,
    6. Anteby EY,
    7. Aviv A,
    8. Vlodavsky I,
    9. Yagel S
    : Localization of heparanase in normal and pathological human placenta. Mol Hum Reprod 8: 566-573, 2002.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Luedders DW,
    2. Bundschuh D,
    3. Hornemann A,
    4. Hoerster JC,
    5. Boemicke P,
    6. Köster F,
    7. Bohlmann MK
    : Heparanase expression in term placentas of diabetic patients and healthy controls. Arch Gynecol Obstet 284: 287-292, 2011.
    OpenUrlPubMed
  6. ↵
    1. Miles JR,
    2. Vallet JL,
    3. Freking BA,
    4. Nonneman DJ
    : Molecular cloning and characterisation of heparanase mRNA in the porcine placenta throughout gestation. Reprod Fertil Dev 21: 757-772, 2009.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kirn-Safran CB,
    2. D'Souza SS,
    3. Carson DD
    . Heparan sulfate proteoglycans and their binding proteins in embryo implantation and placentation. Semin Cell Dev Biol 19: 187-193, 2008.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Parish CR,
    2. Freeman C,
    3. Hulett MD
    : Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471: M99-108, 2001.
    OpenUrlPubMed
  9. ↵
    1. Katz A,
    2. Van-Dijk DJ,
    3. Aingorn H,
    4. Erman A,
    5. Davies M,
    6. Darmon D,
    7. Hurvitz H,
    8. Vlodavsky I
    . Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 4: 996-1002, 2002.
    OpenUrlPubMed
  10. ↵
    1. Vreys V,
    2. David G
    : Mammalian heparanase: what is the message? J Cell Mol Med 11: 427-452, 2007.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Endo K,
    2. Maejara U,
    3. Baba H,
    4. Tokunaga E,
    5. Koga T,
    6. Ikeda Y,
    7. Toh Y,
    8. Kohnoe S,
    9. Okamura T,
    10. Nakajima M,
    11. Sugimachi K
    : Heparanase gene expression and metastatic potential in human gastric cancer. Anticancer Res 21: 3365-3369, 2001.
    OpenUrlPubMed
  12. ↵
    1. Gawthorpe S,
    2. Brown JE,
    3. Arif M,
    4. Nightingale P,
    5. Nevill A,
    6. Carmichael AR
    : Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors. Anticancer Res 34: 2797-2800, 2014.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Jingting C,
    2. Yangde Z,
    3. Yi Z,
    4. Huining L,
    5. Rong Y,
    6. Yu Z
    : Heparanase expression correlates with metastatic capability in human choriocarcinoma. Gynecol Oncol 107: 22-29, 2007.
    OpenUrlPubMed
  14. ↵
    1. Han J,
    2. Hiebert LM
    : Alteration of endothelial proteoglycan and Heparanase gene expression by high glucose, insulin and heparin. Vascul Pharamcol 59: 112-118, 2013.
    OpenUrl
  15. ↵
    1. Bohlmann MK
    : Effects and effectiveness of heparin in assisted reproduction. J Reprod Immunol 90: 82-90, 2011.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Carp H,
    2. Dolitzky M,
    3. Inbal A
    : Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 1: 433-438, 2003.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Gris JC,
    2. Mercier E,
    3. Quere I,
    4. Lavigne-Lissalde G,
    5. Cochery-Nouvellon E,
    6. Hoffet M,
    7. Ripart-Neveu S,
    8. Tailland ML,
    9. Dauzat M,
    10. Mares P
    : Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103: 3695-3699, 2004.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Rey E,
    2. Garneau P,
    3. David M,
    4. Gauthier R,
    5. Leduc L,
    6. Michon N,
    7. Morin F,
    8. Demers C,
    9. Kahn SR,
    10. Magee LA,
    11. Rodger M
    : Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 7: 58-64, 2009.
    OpenUrlCrossRefPubMed
  19. ↵
    1. O'Tierney-Ginn PF,
    2. Lash GE
    : Beyond pregnancy: modulation of trophoblast invasion and its consequences for fetal growth and long-term children's health. J Reprod Immunol 104-105: 37-42, 2014.
    OpenUrl
  20. ↵
    1. Famá EA,
    2. de Souza RS,
    3. Melo CM,
    4. de Melo Pompei L,
    5. Pinhal MA
    : Evaluation of glycosaminoglycans and heparanase in placentas of women with preeclampsia. Clin Chim Acta 437: 155-160, 2014.
    OpenUrl
  21. ↵
    1. Luan Q,
    2. Sun J,
    3. Li C,
    4. Zhang G,
    5. Lv Y,
    6. Wang G,
    7. Li C,
    8. Ma C,
    9. Gao T
    : Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression. Cancer Lett 308: 100-111, 2011.
    OpenUrlPubMed
  22. ↵
    1. Zhang J,
    2. Cao YJ,
    3. Li FY,
    4. Li J,
    5. Yao LB,
    6. Duan EK
    : Effects of fibronectin, VEGF and angiostatin on the expression of MMPs through different signaling pathways in the JEG-3 cells. Am J Reprod Immunol 50: 273-285, 2003.
    OpenUrlPubMed
  23. ↵
    1. Burton GJ,
    2. Charnock-Jones DS,
    3. Jauniaux E
    : Regulation of vascular growth and function in the human placenta. Reproduction 138: 895-902, 2009.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Athanassiades A,
    2. Hamilton GS,
    3. Lala PK
    : Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. Biol Reprod 59: 643-654, 1998.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Cha MS,
    2. Lee MJ,
    3. Je GH,
    4. Kwak JY
    : Endogenous production of nitric oxide by vascular endothelial growth factor down-regulates proliferation of choriocarcinoma cells. Biochem Biophys Res Commun 282: 1061-1066, 2001.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Wirstlein PK,
    2. Mikołajczyk M,
    3. Skrzypczak J
    : Correlation of the expression of heparanase and heparin-binding EGF-like growth factor in the implantation window of nonconceptual cycle endometrium. Folia Histochem Cytobiol 51: 127-134, 2013.
    OpenUrl
  27. ↵
    1. Ferretti C,
    2. Bruni L,
    3. Dangles-Marie V,
    4. Pecking AP,
    5. Bellet D
    : Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update 13: 121-141, 2007.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Pongcharoen S,
    2. Niumsup P,
    3. Sanguansermsri D,
    4. Supalap K,
    5. Butkhamchot P
    : The effect of interleukin-17 on the proliferation and invasion of JEG-3 human choriocarcinoma cells. Am J Reprod Immunol 55: 291-300, 2006.
    OpenUrlPubMed
    1. Zhao M,
    2. Qiu W,
    3. Li Y,
    4. Sang QA,
    5. Wang Y
    : Dynamic change of Adamalysin 19 (ADAM19) in human placentas and its effects on cell invasion and adhesion in human trophoblastic cells. Sci China C Life Sci 52: 710-718, 2009.
    OpenUrlPubMed
    1. Holling TM,
    2. Bergevoet MW,
    3. Wierda RJ,
    4. van Eggermond MC,
    5. van den Elsen PJ
    : Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. Ann NY Acad Sci 1173: 538-544, 2009.
    OpenUrlPubMed
    1. Ikeda K,
    2. Yamasaki K,
    3. Homemoto M,
    4. Yamaue S,
    5. Ogawa M,
    6. Nakao E,
    7. Fukunaga Y,
    8. Nakanishi T,
    9. Utoguchi N,
    10. Myotoku M,
    11. Hirotani Y
    : Efflux transporter mRNA expression profiles in differentiating JEG-3 human choriocarcinoma cells as a placental transport model. Pharmazie 67: 86-90, 2012.
    OpenUrlPubMed
  29. ↵
    1. Jabeen A,
    2. Miranda-Sayago JM,
    3. Obara B,
    4. Spencer PS,
    5. Dealtry GB,
    6. Hayrabedyan S,
    7. Shaikly V,
    8. Laissue PP,
    9. Fernández N
    : Quantified colocalization reveals heterotypic histocompatibility class I antigen associations on trophoblast cell membranes: relevance for human pregnancy. Biol Reprod 89: 94, 2013.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Köster F,
    2. Engel JB,
    3. Schally AV,
    4. Hönig A,
    5. Schröer A,
    6. Seitz S,
    7. Hohla F,
    8. Ortmann O,
    9. Diedrich K,
    10. Buchholz S
    : Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat 116: 273-279, 2009.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Pfaffl MW
    : A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Koçak FE,
    2. Erdoğan E,
    3. Ozyıgıt F,
    4. Yerlıkaya A
    : Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16f10 melanoma cell line. Cell Mol Biol (Noisy-le-grand) 59 Suppl: OL1894-1898, 2013
    OpenUrlPubMed
  33. ↵
    1. Matziolis G,
    2. Erli HJ,
    3. Rau HM,
    4. Klever P,
    5. Bosserhoff AK,
    6. Paar O
    : Heparin accelerates the proliferation of human osteoblasts in vitro. Orthopäde 31: 575-581, 2002.
    OpenUrlPubMed
  34. ↵
    1. Di Simone N,
    2. Di Nicuolo F,
    3. Sanguinetti M,
    4. Ferrazzani S,
    5. D'Alessio MC,
    6. Castellani R,
    7. Bompiani A,
    8. Caruso A
    : Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta 28: 298-304, 2007.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Brenner B,
    2. Hoffman R,
    3. Blumenfeld Z,
    4. Weiner Z,
    5. Younis JS
    : Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83: 693-697, 2000
    OpenUrlPubMed
    1. Brenner B,
    2. Hoffman R,
    3. Carp H,
    4. Dulitsky M,
    5. Younis J
    : Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 3: 227-229, 2005.
    OpenUrlCrossRefPubMed
    1. Dolitzky M,
    2. Inbal A,
    3. Segal Y,
    4. Weiss A,
    5. Brenner B,
    6. Carp H
    : A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 86: 362-366, 2006.
    OpenUrlCrossRefPubMed
    1. Badawy AM,
    2. Khiary M,
    3. Sherif LS,
    4. Hassan M,
    5. Ragab A,
    6. Abdelall I
    : Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol 28: 280-284, 2008.
    OpenUrlCrossRefPubMed
    1. Fawzy M,
    2. Shokeir T,
    3. El-Tatongy M,
    4. Warda O,
    5. El-Refaiey AA,
    6. Mosbah A
    : Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 278: 33-38, 2008.
    OpenUrlCrossRefPubMed
    1. Laskin CA,
    2. Spitzer KA,
    3. Clark CA,
    4. Crowther MR,
    5. Ginsberg JS,
    6. Hawker GA,
    7. Kingdom JC,
    8. Barrett J,
    9. Gent M
    : Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 36: 279-287, 2009.
    OpenUrlAbstract/FREE Full Text
    1. Monien S,
    2. Kadecki O,
    3. Baumgarten S,
    4. Salama A,
    5. Dörner T,
    6. Kiesewetter H
    : Use of heparin in women with early and late miscarriages with and without thrombophilia. Clin Appl Thromb Hemost 15: 636-644, 2009.
    OpenUrlAbstract/FREE Full Text
    1. Clark P,
    2. Walker ID,
    3. Langhorne P,
    4. Crichton L,
    5. Thomson A,
    6. Greaves M,
    7. Whyte S,
    8. Greer IA
    : SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 115: 4162-4167, 2010.
    OpenUrlAbstract/FREE Full Text
    1. Kaandorp SP,
    2. Goddijn M,
    3. van der Post JA,
    4. Hutten BA,
    5. Verhoeve HR,
    6. Hamulyák K,
    7. Mol BW,
    8. Folkeringa N,
    9. Nahuis M,
    10. Papatsonis DN,
    11. Büller HR,
    12. van der Veen F,
    13. Middeldorp S
    : Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 362: 1586-1596, 2010.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Visser J,
    2. Ulander VM,
    3. Helmerhorst FM,
    4. Lampinen K,
    5. Morin-Papunen L,
    6. Bloemenkamp KW,
    7. Kaaja RJ
    : Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 105: 295-301, 2011.
    OpenUrlPubMed
  37. ↵
    1. Nadir Y,
    2. Brenner B
    : Heparanase procoagulant effects and inhibition by heparins. Thromb Res 125(Suppl 2): S72-76, 2010.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Ritchie JP,
    2. Ramani VC,
    3. Ren Y,
    4. Naggi A,
    5. Torri G,
    6. Casu B,
    7. Penco S,
    8. Pisano C,
    9. Carminati P,
    10. Tortoreto M,
    11. Zunino F,
    12. Vlodavsky I,
    13. Sanderson RD,
    14. Yang Y
    : SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17: 1382-1393, 2011.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Hu J,
    2. Song X,
    3. He YQ,
    4. Freeman C,
    5. Parish CR,
    6. Yuan L,
    7. Yu H,
    8. Tang S
    : Heparanase and vascular endothelial growth factor expression is increased in hypoxia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 53: 6810-6817, 2012.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Nadir Y,
    2. Brenner B
    : Heparanase multiple effects in cancer. Thromb Res 133(Suppl 2): S90-94, 2014.
    OpenUrlPubMed
  41. ↵
    1. Taylor CM,
    2. Stevens H,
    3. Anthony FW,
    4. Wheeler T
    : Influence of hypoxia on vascular endothelial growth factor and chorionic gonadotrophin production in the trophoblast-derived cell lines: JEG, JAr and BeWo. Placenta 18: 451-458, 1997.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Goshen R,
    2. Hochberg AA,
    3. Korner G,
    4. Levy E,
    5. Ishai-Michaeli R,
    6. Elkin M,
    7. de Groot N,
    8. Vlodavsky I
    : Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts. Mol Hum Reprod 2: 679-684, 1996.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Dempsey LA,
    2. Plummer TB,
    3. Coombes SL,
    4. Platt JL
    : Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology 10: 467-475, 2000.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Harris LK,
    2. Baker PN,
    3. Brenchley PE,
    4. Aplin JD
    : Trophoblast-derived heparanase is not required for invasion. Placenta 29: 332-337, 2008.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (12)
Anticancer Research
Vol. 34, Issue 12
December 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Growth-modulatory Effects of Heparin and VEGF165 on the Choriocarcinoma Cell-line JEG-3 and its Expression of Heparanase
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Growth-modulatory Effects of Heparin and VEGF165 on the Choriocarcinoma Cell-line JEG-3 and its Expression of Heparanase
MICHAEL K. BOHLMANN, JANA-CHRISTIN HOERSTER, DIANA BUNDSCHUH, PHILIPP BOEMICKE, DOERTE W. LUEDDERS, FRANK KÖSTER
Anticancer Research Dec 2014, 34 (12) 7071-7076;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Growth-modulatory Effects of Heparin and VEGF165 on the Choriocarcinoma Cell-line JEG-3 and its Expression of Heparanase
MICHAEL K. BOHLMANN, JANA-CHRISTIN HOERSTER, DIANA BUNDSCHUH, PHILIPP BOEMICKE, DOERTE W. LUEDDERS, FRANK KÖSTER
Anticancer Research Dec 2014, 34 (12) 7071-7076;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 5-Azacytidine (5-aza) Induces p53-associated Cell Death Through Inhibition of DNA Methyltransferase Activity in Hep3B and HT-29 Cells
  • Prognostic Value of WNT1, NOTCH1, PDGFRβ, and CXCR4 in Oral Squamous Cell Carcinoma
  • Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway
Show more Experimental Studies

Similar Articles

Keywords

  • Heparin
  • VEGF
  • choriocarcinoma
  • Heparanase
  • proliferation
  • PCR
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire